Re: anyone on Lauricidin??

December 13, 2010

hi Cookie,

I've been on Lauricidin for about 5 months. I've talked to at Co. several

times and herx can/does happen. I like all the " anti " stuff it addresses. Also

an alternative to antibiotics. I'm taking both. For me, each hour/day is

different with RA. Is it Lauriciden? antibiotics? etc etc.....or just this

crappy disease??? Sally

rheumatic anyone on Lauricidin??

I have not been on this site in about a month so I'm not sure if any more

people are on Lauricidin. I started taking it it last week and I am having

herx (or maybe my RA got worse).

If you are on Lauricidin and especially if you have had any increase in

symptoms ..please write and let me know. Thanks.

Cooky

RA and fibro since 1997..symptoms have returned 3/10

December 14, 2010

So, Sally what do you think the Lauricidin is doing so far? I just started last

week. I also take it with Minocin.

Thanks

cooky

Subject: Re: rheumatic anyone on Lauricidin??

hi Cookie,

I've been on Lauricidin for about 5 months. I've talked to at Co. several

times and herx can/does happen. I like all the " anti " stuff it addresses. Also

an alternative to antibiotics. I'm taking both. For me, each hour/day is

different with RA. Is it Lauriciden? antibiotics? etc etc.....or just this

crappy disease??? Sally

December 15, 2010

What s Lauricidin?

M.

December 15, 2010

I just copied this off a web site on google. I'm not really into it yet.

But it does not interfere with Minocin so I am cool with it. My doc

suggested it.

I need to read more about it.

information on

<http://www.aviva.ca/../shop/products.asp?itemid=2354 & catid=249> LauricidinR

(monolaurin) for the Health Professional

The antiviral, antibacterial, and antiprotozoal properties of lauric acid

and monolaurin have been recognized for nearly three decades by only a small

number of researchers: their work, however, has resulted in 50 or more

research papers an numerous U.S. and foreign patents. Prof. Dr. Jon J.

Kabara performed the original seminal research in this area of fat research.

Kabara (1968) first patented certain fatty acids (FAs) and their derivatives

(e.g., monoglycerides (MGs) can have adverse effects on various

microorganisms. While nontoxic and approved as a direct food additive by the

FDA, monolaurin adversely affects bacteria, yeast, fungi, and enveloped

viruses.

Kabara found that the properties that determine the anti-infective action of

lipids are related to their structure: e.g., free fatty acids &

monoglycerides. The monoglycerides are active; diglycerides and

triglycerides are inactive. Of the saturated fatty acids, lauric acid has

greater antiviral activity than either caprylic acid (C-8), capric acid

(C-10), or myristic acid (C-14).

Fatty acids and monoglycerides produce their killing/inactivating effects by

several mechanisms. An early postulated mechanism was the perturbing of the

plasma membrane lipid bilayer. The antiviral action attributed to monolaurin

is that of fluidizing the lipids and phospholipids in the envelope of the

virus, causing the disintegration of the microbial membrane. More recent

studies indicate that one antimicrobial effect in bacteria is related to

monolaurin's interference with signal transduction/toxin formation (Projan

et al 1994). Another antimicrobial effect in viruses is due to lauric acid's

interference with virus assembly and viral maturation (Hornung et al 1994).

The third mode of action may be on the immune system itself (Witcher et al,

1993).

Hierholzer and Kabara (1982) first reported the antiviral activity of the

monoglyceride of lauric acid (monolaurin) on viruses that affect humans..

They showed virucidal effects of monolaurin on enveloped RNA and DNA

viruses. This work was done at the Center for Disease Control of the U.S.

Public Health Service. This study was carried out using selected virus

prototypes or recognized representative strains of enveloped human viruses.

All these viruses have a lipid membrane. The presence of a lipid membrane on

viruses makes them especially vulnerable to lauric acid and its derivative

monolaurin. These initial findings have been confirmed by many other

studies.

Research has shown that enveloped viruses are inactivated by added fatty

acids and monoglycerides in both human and bovine milk (Isaacs et al 1991).

Others (Isaacs et al 1986, 1990, 1991, 1992; Thormar et al 1987) have

confirmed Kabara's original statements concerning the effectiveness of

monolaurin.

Some of the viruses inactivated by these lipids are the measles virus,

herpes simplex virus (HSV-1 and -2), herpes family members (HIV, hepatitis

C, vesicular, stomatitis virus (VSV), visna virus, and cytomegalovirus

(CMV). Many of the pathogenic organisms reported to be inactivated by these

antimicrobial lipids are those know to be responsible for opportunistic

infections in HIV -positive individuals. For example, concurrent infection

with cytomegalovirus is recognized as a serious complication for HIV

positive individuals (Macallan et al 1993).

Thus, it would appear imperative to investigate the practical aspects and

the potential benefit of a nutritional supplement such as monolaurin

(Lauricidin) for microbial infected individuals. Until now few nutritionists

in mainstream nutrition community seem to have recognized the added benefit

of antimicrobial lipids in the support of infected patients. These

antimicrobial fatty acids and their derivatives are essentially nontoxic to

man. According to the published research, lauric acid is one of the best

" inactivating " fatty acids, and its monoglyceride is even more effective

than the fatty acid alone (Kabara 1978, Sands et al 1978, Fletcher et al

1985, Kabara 1985).

It should be emphasized that lauric acid cannot be taken orally because it

is severally irritating. LauricidinR on the other hand, a derivative of

lauric acid chemically bonded to glycerol to form monolaurin, can be taken

orally without any problem.

The lipid-coated (envelope) viruses, bacteria and other microorganisms are

dependent on host lipids for their lipid constituents. The variability of

fatty acids in the foods of individuals as well as the variability from de

novo synthesis accounts for the variability of fatty acids in their

membranes.

Monolaurin does not appear to have an adverse effect on desirable gut

bacteria, but rather on only potentially pathogenic microorganisms. For

example, Isaacs et al (1991) reported no inactivation of the common

Esherichiacoli or Salmonella enteritidis by monolaurin, but major

inactivation of Hemophilus influenza, Staphylococcus epidermis and Group B

gram positive streptococcus.

The potentially pathogenic bacteria inactivated by monolaurin include

Listeria monocytogenes, Staphylococcus aureus, Streptococcus agalactiae,

Groups A, streptococci-gram-positive organisms, and some gram-negative

organisms (Vibrio parahaemolyticus and Helicobacter pylori).

Decreased growth of Staphylococcus aureus and decreased production of toxic

shock syndrome toxin-l was shown with monolaurin (Holland et al 1994).

Monolaurin was 5000 times more inhibitory against Listeria monocytogenes

than ethanol (Oh & Marshall 1993). In vitro monolaurin rapidly inactivate

Helicobacter pylori. Of greater significance there appears to be very little

development of resistance of the organism to the bactericidal effects

(Petschow et al 1996) of these natural antimicrobials.

A number of fungi, yeast, and protozoa are also inactivated or killed by

monolaurin. The fungi include several species of ringworm (Isaacs et al

1991). The yeast reported to be affected is Candida albicans (Isaacs et al

1991) The protozoan parasite Giardia lamblia is killed by monoglycerides

from hydrolyzed human milk (Hemell et al 1986, Reiner et al 1986, Crouch et

al 1991, Isaacs et al 1991).

Chlamydia trachomatis is inactivated by monolaurin (Bergsson et al 1998).

Hydrogels containing monocaprin/monolaurin are potent in vitro inactivators

of sexually transmitted viruses such as HSV-2 and HIV-1 and bacteria such as

Neisserian gonorrhea (Thormar 1999).

From: rheumatic [mailto:rheumatic ] On Behalf

Of eson@...

Sent: Wednesday, December 15, 2010 10:23 AM

rheumatic

Subject: rheumatic Re: anyone on Lauricidin??